of high-risk survivors of myocardial infarction with COPD, β-blockers were associated with better outcome [7] .
Nevertheless, in spite of this evidence, physicians still withhold, or seem reluctant to prescribe β-blockers to COPD patients, fearing of provoking bronchospasm and inducing respiratory failure [2] . Regrettably, it is quite unlikely that a large randomized trial to specifically evaluate β-blocker effect in cardiac patients with COPD will ever be performed. In the absence of such ultimate evidence, investigating observational cohorts though specific methods capable to decrease attribution bias would likely increase evidence regarding effects and safety of β-blockers in such patients.
In this respect, robust reassurance with respect to the safety of β-blockers in those patients may finally be at hand, as in this issue of EClinicalMedicine Nielsen et al. [8] provide a thorough assessment of this issue. They leveraged a huge population-based database, which had accrued data about over 1 Million patients enrolled in Denmark between 1995 and 2015, and followed up for more than 6 months. Specifically, Nielsen et al. evaluated the long-term effect of β-blockers on risk of COPD in 301,542 hypertensives who were "new users" of β-blockers, and compared them to 1,000,633 users of any other antihypertensive drugs, with no history of COPD hospital admission. Compared to patients not treated with β-blockers, β-blocker users actually had a significantly lower risk of COPD hospitalization. Of even greater relevance, allcause mortality and COPD mortality rates were also significantly lower. Benefits of β-blockers were already detectable after 6 months of followup [8] . Also, authors were able to capture use of non-β1-selective blockers, and compare to the outcome in COPD patients who instead took β1-selective blockers; importantly, even non-β1-selective blockers proved safe.
Strengths of the study include the use of a nation-wide healthcare database, with nearly 100% population coverage, as well as the fact that the very large sample size allowed use of propensity scores to minimize unknown or unmeasured confounders and selection biases, inherent in a post-hoc observational study. In this respect, one limitation is the lack of information regarding smoking status, which may obviously affect COPD exacerbations. Importantly, it is now appreciated that healthcare databases are useful sources to investigate the epidemiology and to assess longitudinal outcomes of chronic disease -such as COPD-yet, to represent a reliable source, they need to be validated [9] . In this respect, accuracy of diagnosis of COPD in the Danish National Patient Registry had been previously validated, and found to yield an excellent positive predictive value of 93% [10] .
In conclusion, in the absence of prospective trials the study by Nielsen et al. comes as close as possible to reassure us not to be scared of the "wolf", as β-blockers (even older non-β1-selective ones) do prove quite safe to be chronically administered to cardiac patients with COPD. Furthermore, their data solidly reinforced previous indications that β-blocker use are actually of benefit in such patients. Cardiac patients should not be unreasonably deprived of time-honored, guidelinedirected therapy with β-blockers when necessary.
